Cybin Inc
Change company Symbol lookup
Select an option...
CYBN Cybin Inc
IVR-C Invesco Mortgage Capital Inc
MSM MSC Industrial Direct Co Inc
BLUE bluebird bio Inc
ENSV Enservco Corp
ULIHF United Laboratories International Holdings Ltd
ABOIF Aboitiz Equity Ventures Inc
VYNE Vyne Therapeutics Inc
CEAD CEA Industries Inc
BFRI Biofrontera Inc
Go


Based in Canada
Company profile

Cybin Inc. is a Canada-based biopharmaceutical company, working with a network of partners and scientists to create therapeutics for patients to address a multitude of mental health issues. The Company operates in Canada, the United States, United Kingdom and Ireland. The Company is focused on progressing psychedelics to therapeutics by engineering drug discovery platforms, drug delivery systems, formulation approaches and treatment regimens for mental health disorders. The Company’s products in pipeline include EMBARK, Kernel Flow, CYB003 (Deuterated Psilocybin Analog), CYB004 (Deuterated Dimethyltryptamine), and CYB005 (Phenethylamine Derivative). EMBARK is a Psilocybin for mental distress in frontline healthcare workers. Its subsidiaries include Cybin Corp., Natures Journey Inc., Serenity Life Sciences Inc., Cybin US Holdings Inc., Adelia Therapeutics Inc. and Cybin IRL Limited.

Price
Delayed
$0.5885
Day's Change
0.0255 (4.53%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.62
Day's Low
0.545
Volume
(Average)

Today's volume of 397,582 shares is on pace to be in-line with CYBN's 10-day average volume of 511,483 shares.

397,582

Company Profile

Cybin Inc. is a Canada-based biopharmaceutical company, working with a network of partners and scientists to create therapeutics for patients to address a multitude of mental health issues. The Company operates in Canada, the United States, United Kingdom and Ireland. The Company is focused on progressing psychedelics to therapeutics by engineering drug discovery platforms, drug delivery systems, formulation approaches and treatment regimens for mental health disorders. The Company’s products in pipeline include EMBARK, Kernel Flow, CYB003 (Deuterated Psilocybin Analog), CYB004 (Deuterated Dimethyltryptamine), and CYB005 (Phenethylamine Derivative). EMBARK is a Psilocybin for mental distress in frontline healthcare workers. Its subsidiaries include Cybin Corp., Natures Journey Inc., Serenity Life Sciences Inc., Cybin US Holdings Inc., Adelia Therapeutics Inc. and Cybin IRL Limited.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
--
Price/Book (MRQ)
1.66x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

No historic growth available.

Short Interest

June 2022
Current Month
2.8M
Previous Month
2.9M
Percent of Float
2.19%
Days to Cover
4.0653 Days

Share Information

CYBN is in a share class of common stock
Float
119.4M
Shares Outstanding
166.0M
Institutions Holding Shares
48
10.79%

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

No cash flow information available.

Company Officers

No company officers listed.

Address

  • 100 King Street West, Suite 5600
  • Toronto, ON M5X 1C9
  • Canada
  • Phone: 6048060626
  • Fax: 6048060626
  • https://www.cybin.com

Insider Trading

No insider trading activity.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.